Many promising candidates fail beyond Phase I due to formulation challenges such as poor bioavailability, inconsistent exposure, or misaligned release profiles. Early formulation decisions often create significant clinical and commercial risks that lead to costly reformulation later.
Crystal Pharmatech's integrated strategy addresses this by aligning solid-form selection, preformulation, and formulation design with the Target Product Profile (TPP), clinical objectives, and long-term scalability from the very beginning.
Powered by the M3 Framework (Molecule – Material – Medicine), the approach simultaneously evaluates clinical needs (DMPK, pharmacodynamics, safety), material properties (API solid form, stability, processability), and medicine requirements (CQAs, CPPs, control strategy). This ensures disease-relevant exposure, interpretable clinical data, and reduced risk of downstream reformulation.
Clients benefit from expert senior oversight in high-risk early stages, complemented by global execution capabilities across Suzhou (China), Cranbury (New Jersey), and Toronto (Canada).
This First-Time-Right methodology helps biotech and pharmaceutical companies accelerate development, minimize risks, control costs, and build a robust foundation for successful clinical and commercial outcomes.
About Crystal Pharmatech
Crystal Pharmatech is a specialty CRO/CDMO providing integrated solid-state, preformulation, and formulation solutions from preclinical to clinical stages.
Photos: (Click photo to enlarge)
Source: Crystal Pharmatech Co., Ltd.
Read Full Story - First-Time-Right Formulation, Built with Full Lifecycle Intent | More news from this source
Press release distribution by PRLog
